Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL824523 | 0.85 | CYP4F2 (0.41) | DGKACYP4F2CYP4A11ACHE | |
| SCHEMBL18368238 | 0.84 | NAAA (0.45) | DGKACYP4F2CYP4A11ACHENAAA | |
| SCHEMBL13557205 | 0.84 | DGKA (0.45) | DGKACYP4F2CYP4A11ACHENAAA | |
| SCHEMBL14134179 | 0.83 | DGKA (0.33) | DGKACYP4F2CYP4A11ACHE | |
| SCHEMBL2610375 | 0.82 | CYP4F2 (0.40) | CYP4F2CYP4A11ACHE | |
| SCHEMBL13557203 | 0.81 | DGKA (0.32) | DGKACYP4F2CYP4A11 | |
| SCHEMBL2625705 | 0.81 | DGKA (0.32) | DGKACYP4F2CYP4A11 | |
| SCHEMBL11913582 | 0.81 | DGKA (0.47) | DGKACYP4F2CYP4A11NAAA | |
| SCHEMBL13296187 | 0.81 | TRPA1 (0.48) | DGKACYP4F2CYP4A11ACHENAAA | |
| SCHEMBL9968686 | 0.80 | CYP4F2 (0.35) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9274421-B2 | Salt and photoresist composition comprising the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20150118620-A1 | SALT AND PHOTORESIST COMPOSITION COMPRISING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-04-30 | — | — | US | disclosed |
| US-8329377-B2 | Imide compound and chemically amplified resist composition containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100028807-A1 | Imide Compound and Chemically Amplified Resist Composition Containing The Same | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028807-A1 | Imide Compound and Chemically Amplified Resist Composition Containing The Same | IGF1R, CCNA1, MYC | DGKA 2367/4885CYP4F2 2651/4885CYP4A11 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.